Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
28/03/2025 09:25
March 28 (Reuters) - Shenzhen Hepalink Pharmaceutical Group Co Ltd 002399.SZ: PROFIT ATTRIBUTABLE RMB646.7 MILLION FOR YEAR FINAL CASH DIVIDEND OF RMB2.5 PER TEN ORDINARY SHARES FY REVENUE WAS RMB5,258.9 MILLION Further company coverage: 002399.SZ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA